



Bonnie B. Baswell, M.D.
Board Certified Allergy-Immunology
Eric L. Caplan, M.D.
Board Certified Allergy-Immunology

Adult and Pediatric Allergy and Asthma Care

March 2, 2010

To our patients,

You are receiving this letter as our practice management system has identified you or a family member as having asthma currently or at sometime in the past. If this does not apply to you or a family member, please accept our apology and disregard the letter.

The FDA has recently announced labeling changes that pertain to four commonly used asthma medications: Advair and Symbicort, as well as their individual components, Foradil and Serevent. You may or may not have seen mention of this on the local and national news channels or web sites. There may be more media publicity surrounding these medications in the upcoming weeks or months.

We anticipate that the labeling changes may raise a number of questions that you have about the medications that you are taking, particularly if your asthma control plan requires the use of either Advair or Symbicort. We want to address your concerns to the best of our abilities. Therefore, we have opened up follow-up appointment slots to ensure that all of your questions are answered. The majority of openings are on Tuesdays at our south-side clinic location, 1235 Lake Plaza Drive, Suite 218. However, openings are available at all of our three locations.

If you have concerns about the new labeling changes or the media coverage, or if you have questions about your asthma medications, we encourage you to call our office today at 592-1365 to make an appointment, so that we can have a conversation to address these concerns. As always, your health and safety are our number one priority at Colorado Springs Allergy and Asthma Clinic and we look forward to continuing to serve your health needs.

Sincerely,

Bonnie B. Baswell, M.D.

Eric L. Caplan, M.D.